According to the latest report by IMARC Group, titled “Depression Drugs Market Report by Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Others), Disorder Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others), Drug Type (Generic Drugs, Branded Drugs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2025-2033”, the global depression drugs market reached a value of USD 19.2 Billion in 2024. Depression is a serious mental health disorder that negatively affects the way one feels, thinks and acts. It is characterized by persistent feelings of sadness and/or loss of interest. It is a severe illness that can lead to a variety of emotional and physical problems while decreasing the patient’s ability to function at work and home. After identifying specific symptoms and medical history, depression drugs are usually prescribed to the patients to help modify their brain chemistry. The purpose of these medicines is to balance the neurotransmitters in the brain, which affect mood and emotions. Apart from being used to treat depression, these drugs are also widely used to treat other mental health conditions, including anxiety disorders, attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD).
Global Depression Drugs Market Trends:
The increasing awareness regarding the prevalence of depression and other mental illnesses has led a majority of the population to seek professional help, which is primarily driving the market. Hectic lifestyles, improper dietary habits and long working hours, along with social isolation and stressful work environment, have resulted in the development of stress disorders among the working population, which is another major factor boosting the sales of depression drugs. Moreover, the increasing geriatric population is another major growth-inducing factor. The elderly population is more prone to health disorders, which may be followed by mental illnesses. Also, elderlies are more likely to endure the sense of social isolation, especially from the immediate family members and friends, which consequently leads to depression. Furthermore, manufacturers are continually engaging in research and development (R&D) activities to introduce effective variants with minimal side-effects and prolonged results. Looking forward, the market value is projected to reach USD 25.1 Billion by 2033, expanding at a CAGR of 2.9% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Drug Class, Disorder Type, Drug Type, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered | Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd and Sebela Pharmaceuticals |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal